SIBN
SI-BONE, Inc.
$17.25
+0.34 (+2.01%)
At close · Jul 15
Market Cap
$764.58M
Shares
44,349,283
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$200.93M
+20.2%
FY2025
Net Income
-$18.9M
+38.8%
FY2025
Gross Margin
79.57%
+0.5pp
FY2025
Operating Margin
-11.11%
+10pp
FY2025
Diluted EPS
-$0.44
+41.3%
FY2025
Operating Cash Flow
-$675K
+94.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $230M – $233M | $206.22M | $200.93M | $167.18M | $138.89M | $106.41M | $90.15M | $73.39M | $67.3M | $55.38M | $47.98M | |
| — | $42.1M | $41.05M | $35.06M | $29.47M | $15.71M | $10.43M | $8.9M | $6.79M | $4.83M | $5.11M | |
| — | $164.13M | $159.88M | $132.12M | $109.42M | $90.7M | $79.72M | $64.49M | $60.51M | $50.55M | $42.87M | |
| — | — | 79.57% | 79.03% | 78.78% | 85.24% | 88.43% | 87.87% | 89.91% | 91.27% | 89.35% | |
| — | $17.11M | $17.45M | $16.56M | $15.03M | $13.63M | $12.44M | $9.46M | $7.28M | $5.38M | $5.51M | |
| — | $126.35M | $124.22M | $117.05M | $110.25M | $107.73M | $93.88M | $73.79M | $68.25M | $44.5M | $41.65M | |
| — | $40.61M | $40.54M | $33.76M | $31.07M | $28.96M | $25.07M | $19.8M | $20.98M | $12.64M | $13.06M | |
| — | — | $5.77M | $4.38M | $5.43M | $3.45M | $2.09M | $1.13M | $774K | $722K | $1.01M | |
| — | $184.07M | $182.21M | $167.37M | $156.35M | $150.31M | $131.39M | $103.05M | $96.51M | $62.51M | $60.22M | |
| — | -$19.94M | -$22.33M | -$35.25M | -$46.93M | -$59.61M | -$51.67M | -$38.57M | -$36M | -$11.97M | -$17.35M | |
| — | — | -11.11% | -21.08% | -33.79% | -56.02% | -57.31% | -52.55% | -53.5% | -21.61% | -36.16% | |
| — | — | -$16.56M | -$30.87M | -$41.5M | -$56.16M | -$49.58M | -$37.44M | -$35.23M | -$11.24M | -$16.34M | |
| — | $2.56M | $2.63M | $3.44M | $3.46M | $2.82M | $5.37M | $6.1M | $4.95M | $5.11M | $6.2M | |
| — | $5.83M | $6.07M | $7.85M | $6.92M | $1.3M | $186K | $1.1M | $2.55M | $769K | $175K | |
| — | -$27K | -$20K | -$73K | $141K | -$132K | $277K | -$126K | -$2000 | -$1.15M | $340K | |
| — | — | — | — | — | — | — | -$43.7M | -$38.4M | -$17.45M | -$23.04M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | — | — | $0 | $0 | |
| — | -$16.7M | -$18.9M | -$30.91M | -$43.34M | -$61.26M | -$56.57M | -$43.7M | -$38.4M | -$17.45M | -$23.04M | |
| — | — | -9.41% | -18.49% | -31.2% | -57.57% | -62.75% | -59.54% | -57.06% | -31.51% | -48.01% | |
| — | -$16.52M | -$18.33M | -$31M | -$43.23M | -$61.38M | -$56.74M | -$43.64M | -$38.38M | -$17.42M | -$23.11M | |
| USD/shares | — | — | -$0.44 | -$0.75 | -$1.13 | -$1.79 | -$1.71 | -$1.50 | — | — | — |
| USD/shares | — | — | -$0.44 | -$0.75 | -$1.13 | -$1.79 | -$1.71 | -$1.50 | — | — | — |
| shares | — | — | 42.96M | 41.47M | 38.43M | 34.2M | 33.15M | 29.06M | 24.71M | 7.95M | 3.47M |
| shares | — | — | 42.96M | 41.47M | 38.43M | 34.2M | 33.15M | 29.06M | 24.71M | 7.95M | 3.47M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2019: $111K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 2.22×
EV/EBIT
—
Medical Devices median 21.48×
P/E (TTM)
—
Medical Devices median 27.36×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| United States | $191,079,000 | $158,416,000 | $130,621,000 | $98,751,000 | $82,739,000 | $68,118,000 | $61,843,000 |
| Non Us | $9,846,000 | $8,762,000 | $8,265,000 | $7,658,000 | $7,413,000 | $5,269,000 | $5,458,000 |